Lixisenatide vs Mazdutide
Head-to-head comparison of Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) and Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Lixisenatide | Mazdutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Exendin-4-derived GLP-1 receptor agonist | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist |
| Molecular Weight | 4858 Da | ~5,000 Da |
| Half-Life | 2-4 hours | 5-7 days |
| Amino Acids | 44 | 37 |
| Typical Dose | 10-20 mcg daily | 1-6 mg weekly in obesity trials |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 400 | 28 |
| Research Status | Approved | Clinical |
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Research Overview
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.